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little is known about how this could affect beneficial effector im-
mune responses. In the current study, we used a recombinant
adeno-associated virus (AAV) expressing IL-2 to permanently re-
lease IL-2 and assess its effect on immune responses during vac-
cination, infection, cancer developement and pregnancy. We used
single injections of AAV IL-2 at 2 doses. 109 virus particles (v.p.)
increased CD25 and Foxp3 expression in Tregs, had minimal ef-
fects on Treg numbers and delayed but did not prevent the oc-
currence of type 1 diabetes (T1D) in NOD mice; 1010 v.p. enabled
sustained stimulation and expansion of Tregs without inducing
Teff activation and prevented T1D in NOD mice. After several
weeks of IL-2 production at these two doses, mice could normally
(i) eradicate a viral challengewith flu, (ii) mount immune responses
to vaccination, and (iii) have normal pregnancies with pups that
developed normally. They also had no change in occurrence and
growth of chemically induced tumors, as well as in growth of
transplanted tumors. Altogether, chronic low doses IL-2 treatment
appears safe and does not affect usefull effector immune responses.
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Alzheimer’s disease (AD), the major cause of dementia, is
characterized by two hallmarks, amyloid pathology and neuro-
fibrillary tangles of hyperphosphorylated Tau protein. We re-
cently described the therapeutic effect of cerebral cholesterol
24-hydroxylase (CYP46A1) overexpression on amyloid pathol-
ogy of APP23 mice (Hudry et al.).
The aim of this work was to investigate the consequences of
CYP46A1 overexpression on the Tau component of AD.
CYP46A1 overexpression was induced in the THY-Tau22
transgenic mouse model by stereotactic injection of an AAV
vector carrying the human CYP46A1 gene in cortex and hippo-
campus. An AAV vector coding a mutated inactive CYP46A1
enzyme was used as a control. Injected animals were compared
to normal control littermates.
In contrast to THY-Tau22mice treated with inactive CYP46A1,
THY-Tau22 mice overexpressing functional CYP46A1 enzyme
showed normal memory abilities in two behavioral tasks (Morris
Water Maze and Y-maze). Thus CYP46A1 overexpression res-
cues the main cognitive dysfunction of this model.
Hyperphosphorylation of Tau and astrogliosis that characterize
this THY-Tau22 model were not modified by CYP46A1 over-
expression. Lipidomic analysis evidenced modified lipid profile in
THY-Tau22 mice. CYP46A1 overexpression allowed complete
restoration of this profile and increased expression of genes im-
plicated in cholesterol synthesis in both hippocampus and cortex.
Mechanisms that underlie the neuroprotective effect of
CYP46A1 overexpression in THY-Tau22 mouse are under in-
vestigation. Overall, phenotypic improvement of both APP23
and THY-Tau22 mice suggest that CYP46A1 is a relevant thera-
peutic target on AD.
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Dystrophic Epidermolysis Bullosa (DEB) is a group of genetic
skin disorders inherited in a dominant (DDEB) or recessive
(RDEB) manner and characterised by severe skin and mucosae
blistering after mild traumas. DEB is caused by mutations in
COL7A1 encoding type VII collagen that assembles into an-
choring fibrils forming key dermo-epidermal adhesion struc-
tures. To date, there is no specific treatment for DEB. Exon
skipping strategy consists in modulating the splicing of a pre-
messenger RNA to induce the skipping of a mutated exon. Exons
73, 74 and 80 of COL7A1 are of particular interest because they
carry several recurrent mutations and their excision preserves the
open reading frame. We first demonstrated the dispensability of
these exons for type VII collagen function in an in vivo xenograft
model using RDEB cells transduced with retroviral vectors con-
taining COL7A1 cDNAs deleted of the sequences of these exons.
We then transfected primary RDEB keratinocytes and fibroblasts
with antisense oligoribonucleotides (AONs) targeting key splic-
ing regulatory elements (exonic splicing enhancers and/or ac-
ceptor sites) to induce efficient skipping of these exons (50% up to
90%). Western blot and immunocytochemistry analyses demon-
strated significant collagen VII re-expression in cells from two
RDEB patients, one homozygous for a nonsense mutation in exon
80, the other compound heterozygous for frameshift mutations in
exon 73 and 80. We now aim to demonstrate the feasibility of this
approach in vivo using animal models. If successful, this ap-
proach would offer potential for treating both RDEB and DDEB
patients using local or systemic administration of AONs.
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Spinal muscular atrophy is a recessive disease caused by
mutations in the SMN1 gene, which encodes a protein (SMN)
involved in RNA processing whose absence dramatically affects
the survival of motor neurons. In Man, the severity of the disease
correlates with the SMN2 gene copy number, which varies from
individual to individual.
SMN2 differs from SMN1 by 5 nucleotides, only one of which
is in the coding sequence: it is a silent C to T change located at the
sixth nucleotide of exon 7. Thus, SMN2 encodes the same SMN
protein as SMN1. However, the single nucleotide change affects
the definition of exon 7 during splicing such that about 90% of
SMN2 mRNAs lack this exon.
Here, we show that SMN activity can be restored in SMA cells
by using tricyclo-DNA (Tc-DNA) antisense oligonucleotides
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annealing either the exon 7 terminal stem loop (TSL) or a nearby
intron 7 splice silencer (ISS) of the SMN2 pre-mRNA. RT-PCR
showed that about 30% and 60% of SMN2 mRNAs were rescued
after treatment with Tc-DNA analogues annealing the TSL and
ISS, respectively. For Tc-DNA[ISS], SMN levels were close to
normal in Western blot analysis. Finally, immuno-staining re-
vealed that rescued SMN was properly located in nuclear gems.
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We developed and validated sensitive genotoxicity assays
based onCdkn2a-/- orwild type (WT)mice to assess the biosafety of
lentiviral vectors (LV) designed for liver gene transfer. As a posi-
tive control of insertional mutagenesis, we used a LV carrying
Enhanced Transthyretin enhancer/promoter (ET) cloned in the
Long Terminal Repeats (LV.ET.LTR) which induced hepatocellu-
lar carcinoma (HCC) in 30% of Cdkn2a-/-mice (p< 0.01) and 75% of
WT mice in combination with CCl4 treatment (p< 0.01).
We exploited these mouse models to test the safety of Self-
Inactivating LVs developed for the therapy of haemophilia B
which express factor IX under the control of ET (SINLV.ET.FIX).
Systemic administration of SINLV.ET.FIX did not induce HCCs
neither in tumor prone Cdkn2a-/- (N= 39) nor in WT mice+CCl4
(N= 23). We retrieved a total of 9215 unique insertion sites from
LV.ET.LTR- and SINLV.ET.FIX-treated mice. None of the previ-
ously validated cancer genes recurrently targeted by the oncogenic
LV.ET.LTR was hit by SINLV.ET.FIX-integrations. However,
SINLV.ET.FIX-insertions clustered at different Common Insertion
Sites (CIS). Importantly, we found that: 1) SINLV.ET.FIX-CIS had
a lower CIS power compared to LV.ET.LTR-CIS (p< 0.01); 2)
SINLV.ET.FIX-CIS were represented by a lower percentage of
sequence reads compared to LV.ET.LTR-CIS (p< 0.001); 3) SINL-
V.ET.FIX-CIS did not show any skewing towards genes involved
in cancer; 4) SINLV.ET.FIX-CIS were embedded in large genomic
areas with high LV integration incidence. These findings indicate
that SINLV.ET.FIX-CIS are the result of LV-intrinsic integration
biases rather than the result of selection.
Our data indicate that SINLV.ET.FIX represents a safe vector
design for hepatocytes gene transfer for different gene therapy
applications.
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Clonal dominance and leukemia are potential side effects of
hematopoietic stem cell gene therapy. High-throughput methods
enable fast identification of individual stem cell-derived clones.
Quantitative real-time PCR (QRT-PCR) has been shown to be an
accurate method to quantify individual transduced cell clones.
However, due to frequently scarce target material large scale
clonal analysis of multiple clones by QRT-PCR is hardly
achievable.
The aim of this study was to explore the potential of highly
sensitive techniques for vector insertion site analysis (LAM-PCR,
nonrestrictive LAM-PCR) to describe clonal compositions in gene
therapy compared to QRT-PCR. Therefore, we designed artificial
insertion sites (arIS) of different sizes which were mixed for
mimicking defined clonal situations in clinical settings ranging
from balanced clonality to monoclonality in an in vitro setting. We
subjected all arIS mixes to either linear amplification-mediated
PCR (LAM-PCR) or nonrestrictive LAM-PCR (nrLAM-PCR) both
combined with 454 sequencing compared to QRT-PCR. By per-
forming this important first technical comparison we showed that
nrLAM-PCR/454-based clonal assessment is in the same range as
the results obtained with QRT-PCR. To prove whether nrLAM-
PCR/454 can prospectively facilitate clonality analyses in clinical
gene therapy studies, we followed clonal kinetics of two clones
detected in a patient enrolled in a clinical trial using both, nrLAM-
PCR/454 and QRT-PCR. In line with the previous in vitro data,
nrLAM-PCR/454 has shown to tightly reflect QRT-PCR-mea-
sured clonal contributions. We show for the first time a feasible
high-throughput strategy to reliably monitor clonality in large-
scale analyses of gene-marked cells in clinical gene therapy trials.
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Vector integrations in ADA (adenosine deaminase) deficient-
SCID patients treated with hematopoietic stem cells (HSC) or
mature lymphocytes (PBL) gene therapy (GT) introduce a univ-
ocal tag in each infused target cell. These studies allow tracking
of single T-cell clones and studying the survival potential and
hierarchical relationships of naive and memory subpopulations
directly in vivo in humans. We analyzed at high-throughput
level the integrome of sorted T cell subtypes from PBL-GT pa-
tients years after last infusion of gene corrected lymphocytes.
Strikingly, we found that transduced T cells with an apparent
naı¨ve phenotype (CD45RA +/62L + ) share the highest percent-
age of insertions (41.2%) with other T subpopulations while still
surviving in vivo 10 years after infusion. A novel T-cell type (T
memory stem cell, TSCM) with long-term survival capacity
coupled with naive-like plasticity, has been recently identified as
CD45RA +/62L +/CD95 + . Interestingly, we found that the vast
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